Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrew Judge"'
Autor:
Hui Hu, Daria Neyroud, Chandler S. Callaway, Andrew Judge, Sarah M. Judge, Rachel L. Nosacka, Jose G. Trevino
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 2, Pp 421-442 (2021)
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 2, Pp 421-442 (2021)
Background Skeletal muscle wasting is a devastating consequence of cancer that affects up to 80% of cancer patients and associates with reduced survival. Herein, we investigated the biological significance of Forkhead box P1 (FoxP1), a transcriptiona
Autor:
Dan Delitto, Jose G. Trevino, Rohan Patel, Sarah M. Judge, Andrew Judge, Rachel L. Nosacka, Andrea E. Delitto
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 3, Pp 820-837 (2020)
Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 3, Pp 820-837 (2020)
Background Cancer cachexia is a life‐threatening metabolic syndrome that causes significant loss of skeletal muscle mass and significantly increases mortality in cancer patients. Currently, there is an urgent need for better understanding of the mo
Autor:
Brandon M. Roberts, Gordon S. Mitchell, David D. Fuller, Andrew Judge, Alec Simon, Daryl P. Fields
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 1, Pp 63-72 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle
Background Cancer cachexia is an insidious process characterized by muscle atrophy with associated motor deficits, including diaphragm weakness and respiratory insufficiency. Although neuropathology contributes to muscle wasting and motor deficits in
Autor:
John D. Ganey, Robert W. Jackman, Susan C. Kandarian, Andrew Judge, Jesse D. Moreira, Andrea E. Delitto, Sarah M. Judge, Rachel L. Nosacka
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle. 9:1109-1120
BACKGROUND Cancer cachexia is a metabolic wasting syndrome that is strongly associated with a poor prognosis. The initiating factors causing fat and muscle loss are largely unknown. Previously, we found that leukaemia inhibitory factor (LIF) secreted